7RG0 Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Regulus Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$3.26 |
| 52 Week Low | US$1.02 |
| Beta | 1.62 |
| 11 Month Change | -12.90% |
| 3 Month Change | -27.42% |
| 1 Year Change | 6.30% |
| 33 Year Change | -77.50% |
| 5 Year Change | -77.69% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7RG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -0.7% | 1.0% |
| 1Y | 6.3% | -17.7% | 11.2% |
Return vs Industry: 7RG0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 7RG0 underperformed the German Market which returned 10.7% over the past year.
Price Volatility
| 7RG0 volatility | |
|---|---|
| 7RG0 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7RG0's share price has been volatile over the past 3 months.
Volatility Over Time: 7RG0's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 31 | Jay Hagan | www.regulusrx.com |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. Fundamentals Summary
| 7RG0 fundamental statistics | |
|---|---|
| Market cap | €91.17m |
| Earnings (TTM) | -€31.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs 7RG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7RG0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$25.60m |
| Gross Profit | -US$25.60m |
| Other Expenses | US$9.79m |
| Earnings | -US$35.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7RG0 perform over the long term?
See historical performance and comparison